DavidDingliMDPhD, FRCP, FRCPEd, FACP, CBiol, FRSB

PubMed

• Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failures.
  Saurabh Zanwar, Morie A Gertz, Eli Muchtar, Francis K Buadi, Taxiarchis Kourelis, Wilson Gonsalves, Ronald S Go, Suzanne Hayman, Prashant Kapoor, Moritz Binder, Josell...> ;Leukemia. 2024 Apr 9
• Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomide.
  Utkarsh Goel, Charalampos Charalampous, Prashant Kapoor, Moritz Binder, Francis K Buadi, David Dingli, Angela Dispenzieri, Amie Fonder, Morie A Gertz, Wilson I Gonsalv...> ;Blood Cancer Journal. 2024 Mar 26
• Mode of progression in smoldering multiple myeloma: a study of 406 patients.
  Abdallah, N., Lakshman, A., Kumar, S., Cook, J., Binder, M., Kapoor, P., Dispenzieri, A., Gertz, M., Lacy, M., Hayman, S., Buadi, F., Dingli, D., Lin, Y., Kourelis, T....> ;Blood Cancer Journal. 2024 Jan 17
• Muscle and fat composition in patients with newly diagnosed multiple myeloma.
  Abdallah, N., Nagayama, H., Takahashi, N., Gonsalves, W., Fonder, A., Dispenzieri, A., Dingli, D., Buadi, F., Lacy, M., Hobbs, M., Gertz, M., Binder, M., Kapoor, P., W...> ;Blood Cancer Journal. 2023 Dec 12
• Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myeloma.
  Charalampous, C., Goel, U., Kapoor, P., Binder, M., Buadi, F., Cook, J., Dingli, D., Dispenzieri, A., Fonder, A., Gertz, M., Gonsalves, W., Hayman, S., Hobbs, M., Hwa,...> ;Blood Cancer Journal. 2023 Dec 11
• Paroxysmal nocturnal hemoglobinuria: Review of the patient experience and treatment landscape.
  Waheed, A., Shammo, J., Dingli, D.> ;Blood Reviews. 2024 Mar 1
• Predictors and Impact of Timing of Disease Progression Following Primary Therapy in Multiple Myeloma.
  Sarah Goldman-Mazur, Alissa Visram, S Vincent Rajkumar, Prashant Kapoor, Angela Dispenzieri, Martha Q Lacy, Morie A Gertz, Francis K Buadi, Suzanne R Hayman, David Din...> ;Clinical Lymphoma, Myeloma & Leukemia. 2024 Mar 1
• Mode of Progression in Smoldering Multiple Myeloma: A study of 406 patients.
  S Rajkumar, Nadine Abdallah, Arjun Lakshman, Shaji Kumar, Joselle Cook, Moritz Binder, Prashant Kapoor, Angela Dispenzieri, Morie Gertz, Martha Lacy, Suzanne Hayman, F...> ;Research Square. 2023 Oct 23
• Analysis of Costs per Responder in US Adults with Paroxysmal Nocturnal Hemoglobinuria with a Suboptimal Response to Prior Eculizumab Treatment.
  Jesse Fishman, Seri Anderson, Sandra E Talbird, David Dingli> ;Hematology Reports. 2023 Oct 13
• The cost-effectiveness of pegcetacoplan in complement treatment-naïve adults with paroxysmal nocturnal hemoglobinuria in the USA.
  Jesse Fishman, Koo Wilson, Aleksandra Drzewiecka, Michał Pochopień, David Dingli> ;Journal of Comparative Effectiveness Research. 2023 Oct 1
• Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapy.
  Charalampos Charalampous, Utkarsh Goel, Prashant Kapoor, Moritz Binder, Francis K Buadi, Joselle Cook, David Dingli, Angela Dispenzieri, Amie L Fonder, Morie A Gertz, ...> ;Blood Advances. 2023 Aug 22
• 1 citations
  Long-term outcomes of allogeneic stem cell transplant in multiple myeloma.
  Walker M Schmidt, Nirosha D Perera, Francis K Buadi, Suzanne R Hayman, Shaji K Kumar, Angela Dispenzieri, David Dingli, Joselle Cook, Martha Q Lacy, Prashant Kapoor, N...> ;Blood Cancer Journal. 2023 Aug 18
• 2 citations
  Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas.
  Udit Yadav, Shaji K Kumar, Linda B Baughn, Angela Dispenzieri, Patricia Greipp, Rhett Ketterling, Dragan Jevremovic, Francis K Buadi, David Dingli, Martha Q Lacy, Rafa...> ;Blood. 2023 Nov 30
• 5 citations
  Natural history, predictors of development of extramedullary disease, and treatment outcomes for patients with extramedullary multiple myeloma.
  Saurabh Zanwar, Matthew Ho, Yi Lin, Prashant Kapoor, Moritz Binder, Francis K Buadi, Angela Dispenzieri, David Dingli, Amie Fonder, Morie A Gertz, Wilson Gonsalves, Su...> ;American Journal of Hematology. 2023 Oct 1
• A phase 1/2 of carfilzomib and melphalan conditioning for autologous stem cell transplantation for multiple myeloma (CARAMEL).
  Alissa Visram, Suzanne R Hayman, Angela Dispenzieri, Prashant Kapoor, Martha Q Lacy, Morie A Gertz, Francis K Buadi, David Dingli, Rahma Warsame, Taxiarchis Kourelis, ...> ;American Journal of Hematology. 2023 Aug 1
• Radiovirotherapy at twenty.
  David Dingli> ;Molecular Therapy Oncolytics. 2023 Jun 15
• Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapy.
  Charalampos Charalampous, Utkarsh Goel, Prashant Kapoor, Moritz Binder, Francis K Buadi, Joselle Cook, David Dingli, Angela Dispenzieri, Amie L Fonder, Morie A Gertz, ...> ;Blood Advances. 2023 Aug 22
• 3 citations
  ML-based sequential analysis to assist selection between VMP and RD for newly diagnosed multiple myeloma.
  Sung-Soo Park, Jong Cheol Lee, Ja Min Byun, Gyucheol Choi, Kwan Hyun Kim, Sungwon Lim, David Dingli, Young-Woo Jeon, Seung-Ah Yahng, Seung-Hwan Shin, Chang-Ki Min, Jam...> ;NPJ Precision Oncology. 2023 May 20
• Relationship of paroxysmal nocturnal hemoglobinuria (PNH) granulocyte clone size to disease burden and risk of major vascular events in untreated patients: results fro...
  David Dingli, Jaroslaw P Maciejewski, Loree Larratt, Ronald S Go, Britta Höchsmann, Ke Zu, Philippe Gustovic, Alexander D Kulagin> ;Annals of Hematology. 2023 Jul 1
• 1 citations
  Conditional survival in multiple myeloma and impact of prognostic factors over time.
  Nadine H Abdallah, Alexandra N Smith, Susan Geyer, Moritz Binder, Patricia T Greipp, Prashant Kapoor, Angela Dispenzieri, Morie A Gertz, Linda B Baughn, Martha Q Lacy,...> ;Blood Cancer Journal. 2023 May 15
• Daratumumab-lenalidomide and daratumumab-pomalidomide in relapsed lenalidomide-exposed or refractory multiple myeloma.
  Muhamad Alhaj Moustafa, Ricardo Parrondo, Mays F Abdulazeez, Vivek Roy, Taimur Sher, Victoria R Alegria, Rahma M Warsame, Rafael Fonseca, Ahsan Rasheed, Wilson I Gonsa...> ;Anti-Cancer Drugs. 2024 Jan 1
• 7 citations
  Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma.
  Radhika Bansal, Mizba Baksh, Jeremy T Larsen, Matthew A Hathcock, David Dingli, A Keith Stewart, Prashant Kapoor, Taxiarchis Kourelis, Suzanne R Hayman, Rahma M Warsam...> ;Blood Cancer Journal. 2023 Apr 5
• 5 citations
  Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma.
  Utkarsh Goel, Charalampos Charalampous, Prashant Kapoor, Moritz Binder, Francis K Buadi, David Dingli, Angela Dispenzieri, Amie Fonder, Morie A Gertz, Wilson I Gonsalv...> ;Blood Cancer Journal. 2023 Jan 11
• 4 citations
  Thrombosis in multiple myeloma: Risk estimation by induction regimen and association with overall survival.
  Charalampos Charalampous, Utkarsh Goel, Prashant Kapoor, Moritz Binder, Francis K Buadi, David Dingli, Angela Dispenzieri, Amie L Fonder, Morie A Gertz, Wilson Gonsalv...> ;American Journal of Hematology. 2023 Mar 1
• The impact of Post-Transplant doxycycline in AL amyloidosis - updated results after Long-Term follow up.
  Nadine Abdallah, Angela Dispenzieri, Eli Muchtar, Francis K Buadi, Prashant Kapoor, Martha Q Lacy, Yi L Hwa, Amie Fonder, Miriam A Hobbs, Suzanne R Hayman, Nelson Leun...> ;Amyloid. 2023 Sep 1
• Join now to see all

Journal Articles

• Safety and Efficacy of Propylene Glycol-Free Melphalan as Conditioning in Patients with AL Amyloidosis Undergoing Stem Cell Transplantation  
  Nelson Leung, Prashant Kapoor, Taxiarchis V Kourelis, Eli Muchtar, Angela Dispenzieri, M Hasib Sidiqi, Martha Q Lacy, Wilson I Gonsalves, Shaji K Kumar, Mohammed A Alj..., Nature
• Relapse After Complete Response in Newly Diagnosed Multiple Myeloma: Implications of Duration of Response and Patterns of Relapse  
  Angela Dispenzieri, Francis K Buadi, Morie A Gertz, Martha Q Lacy, Nelson Leung, Amie L Fonder, Wilson I Gonsalves, Yi Lisa Hwa, Taxiarchis Kourelis, Surbhi Sidana, Ro..., Nature
• Primary Systemic Amyloidosis in Patients with Waldenström Macroglobulinemia  
  Angela Dispenzieri, Eli Muchtar, Ronald Go, Saurabh Zanwar, Surbhi Sidana, Francis Buadi, Stephen M Ansell, Prashant Kapoor, David Dingli, Thomas Habermann, Shaji Kuma..., Nature
• Daratumumab-Based Therapy in Patients with Heavily-Pretreated AL Amyloidosis  
  Saurabh Zanwar, Angela Dispenzieri, Wilson Gonsalves, David Dingli, Jithma P Abeykoon, Martha Q Lacy, Shaji Kumar, Nelson Leung, Morie A Gertz, Eli Muchtar, Francis Bu..., Nature
• Optimizing Deep Response Assessment for AL Amyloidosis Using Involved Free Light Chain Level at End of Therapy: Failure of the Serum Free Light Chain Ratio  
  Morie A Gertz, David Dingli, Miriam Hobbs, John A Lust, Ronald S Go, Amie Fonder, Yi Lin, Shaji K Kumar, Prashant Kapoor, Taxiarchis V Kourelis, S Vincent Rajkumar, Ro..., Nature
• Comparable Outcomes Using Propylene Glycol-Free Melphalan for Autologous Stem Cell Transplantation in Multiple Myeloma  
  Morie A Gertz, Shaji K Kumar, Martha Q Lacy, Prashant Kapoor, Suzanne R Hayman, Robert C Wolf, William J Hogan, Wilson I Gonsalves, Angela A Dispenzieri, David Dingli,..., Nature
• Utilization of Hematopoietic Stem Cell Transplantation for the Treatment of Multiple Myeloma: A Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consen...  
  John A Lust, Shaji K Kumar, Morie A Gertz, P Leif Bergsagel, Angela Dispenzieri, Francis K Buadi, Prashant Kapoor, Angela A Mayo, Wilson I Gonsalves, Rafael Fonseca, R..., Nature
• Join now to see all

Abstracts/Posters

• Influence of Cytogenetics in Patients with Relapsed Refractory Multiple Myeloma Treated with Oral Selinexor and Dexamethasone: A Post-Hoc Analysis of the STORM Study
  David Dingli, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Delayed Neutrophil Engraftment in Patients Receiving Daratumumab As Part of Their First Induction Regimen for Multiple Myeloma
  David Dingli, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Prognostic Implications of Serum Monoclonal Protein Positivity By Mass-Fix in Bone Marrow Minimal Residual Disease Negative (MRD-) Patients with Multiple Myeloma
  David Dingli, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Impact of sFLC Ratio on Outcome in Patients with MM: Validating the Utility of sFLC in Response Definition
  David Dingli, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Prospective Pilot Study of Ixazomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed or Relapsed/Refractory POEMS Syndrome
  David Dingli, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A Novel Approach to Risk Stratification in Multiple Myeloma Using ISS Stage and FISH
  David Dingli, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Peak Lymphocyte Count after CAR T Infusion Is a Clinically Accessible Test That Correlates with Clinical Response in Axicabtagene Ciloleucel Therapy for Lymphoma
  David Dingli, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Mortality of Patients with Multiple Myeloma after the Introduction of Novel Therapies in the United States
  David Dingli, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients with Newly Diagnosed Multiple Myeloma
  David Dingli, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Waldenstr_m Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity?
  David Dingli, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Phase 2 Trial of Daratumumab, Ixazomib, Lenalidomide and Modified Dose Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma
  David Dingli, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Optimal Therapy for Relapsed AL Amyloidosis Post Autologous Stem Cell Transplant
  David Dingli, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Use of Maintenance Therapy Post Autologous Stem Cell Transplantation Outside of Clinical Trial Setting for Multiple Myeloma: Single Institution Experience
  David Dingli, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Utilizing Multiparametric Flow Cytometry to Identify Patients with Primary Plasma Cell Leukemia at Diagnosis
  David Dingli, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had Plasmacy...
  David Dingli, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• Ibrutinib Therapy in Patients with Waldenstrom Macroglobulinemia: Outcomes Outside of Clinical Trial Setting 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Prognostic Value of Clone Size in Paroxysmal Nocturnal Hemoglobinuria (PNH) for Thrombotic Events in Untreated Patients in the International PNH Registry 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Bortezomib, Lenalidomide and Dexamethasone (VRD) Followed By Autologous Stem Cell Transplant for Newly Diagnosed Multiple Myeloma; The Mayo Clinic Experience 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Long-Term Survivorship with Active Multiple Myeloma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all